FOR ADULTS WITH PSORIATIC ARTHRITIS (PsA), ANKYLOSING SPONDYLITIS (AS), OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (nr-axSpA).

Cosentyx®
(secukinumab)

THE FIRST AND ONLY IV INFUSION OF ITS KIND.*



COSENTYX PATIENT† **BILL**

*The first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.

†This brochure contains photos of actual patients who have taken COSENTYX and have been compensated for their time. Individual results may vary. Patients pictured in this brochure administer COSENTYX with subcutaneous self-injections.

INDICATIONS

COSENTYX® (secukinumab) is a prescription medicine used to treat:

- people 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)
- people 2 years of age and older with active psoriatic arthritis (PsA)
- adults with active ankylosing spondylitis (AS)
- adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation
- people 4 years of age and older with active enthesitis-related arthritis (ERA)

Please see additional Important Safety Information throughout brochure.
Tap here for full Prescribing Information, including Medication Guide.

Visit **COSENTYX.com** for more information.

Cosentyx® (secukinumab)

ABOUT COSENTYX®

COSENTYX is approved to treat psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Initially approved as a subcutaneous (SC) injection (injection under the skin), COSENTYX has been proven to provide real results for people with these conditions.

It's the first and only IL-17A treatment available through IV infusion.*

COSENTYX can also be given through IV infusions to adults with PsA, AS, nr-axSpA. Now that you and your doctor have made the decision to start COSENTYX, this brochure can help you further understand what to expect before your first IV infusion.

*As of October 2023.

TABLE OF CONTENTS

IMPORTANT SAFETY INFORMATION

Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have died from these infections.

- Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. **Do not take COSENTYX if you have an active TB infection**.

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

REAL RESULTS. REAL RELIEF.*

PSORIATIC ARTHRITIS (PsA)

COSENTYX® delivers real relief from the multiple symptoms of psoriatic arthritis and helps to deliver less joint pain, swelling, tenderness, and back pain‡ as well as clearer skin.

60% of adults in a clinical trial taking COSENTYX 150 mg (SC) saw at least a **20% improvement in PsA symptoms at 16 weeks vs 18% on placebo.**

77% of adults taking COSENTYX 300 mg (SC) in another clinical trial **had no increase in joint damage at 6 months vs 68% on placebo.†**

*Results shown in clinical trials using subcutaneous (SC) administration (injection under the skin). The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.
†71% of patients had no increase in joint damage at 6 months in the 150-mg (SC) group.
‡Based on data from X-rays of the hands and feet at 6 months.

IMPORTANT SAFETY INFORMATION (cont)

Before starting COSENTYX, tell your doctor if you:

- are being treated for an infection
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

COSENTYX TREATS MULTIPLE PsA SYMPTOMS



LESS JOINT PAIN AND SWELLING

63%

of adults got relief from joint symptoms, including pain and swelling, and saw improved ability to function vs 27% on placebo.§

CLEARER SKIN

54%

of adults with psoriasis skin plaques saw clearer skin vs 9% on placebo.§

LESS OVERALL BACK SYMPTOMS

63%

of adults saw improvement in overall back symptoms, including pain, stiffness, and mobility vs 31% on placebo.‡

LESS TENDERNESS

56%

of adults saw a complete reduction in enthesitis, or the swelling where tendons and ligaments connect to the joints vs 35% on placebo.§

LESS SWELLING IN FINGERS AND TOES

66%

of adults saw a complete reduction in dactylitis, or swelling in toes and fingers vs 32% on placebo.§

‡In a clinical trial of adults taking COSENTYX 300 mg (SC) as their first biologic at 12 weeks.
§In a clinical trial of adults taking COSENTYX 300 mg (SC) at 16 weeks.

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

REAL RESULTS. REAL RELIEF.*

ANKYLOSING SPONDYLITIS (AS)

In as little as 16 weeks, twice as many people treated with COSENTYX® 150 mg (SC) achieved **at least a 20% improvement in overall symptoms** vs those taking placebo (61% vs 28%).

*Results shown in clinical trials using subcutaneous (SC) administration (injection under the skin). The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.

3X IMPROVEMENT IN MOBILITY†

Reported by those in a clinical trial taking COSENTYX and who completed a questionnaire that asked how difficult it was to perform physical activities.†

†At 16 weeks, patients saw 35% improvement in mobility while taking COSENTYX vs 11% with placebo.

2X MORE BACK PAIN RELIEF‡

‡At 16 weeks, patients taking COSENTYX saw 43% improvement in back pain vs 16% with placebo.

IMPORTANT SAFETY INFORMATION (cont)

What are the possible side effects of COSENTYX?

COSENTYX may cause serious side effects, including:

Inflammatory bowel disease
New cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

IMPORTANT SAFETY INFORMATION (cont)

Serious allergic reactions
Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; skin rash or hives (red, itchy bumps).

If you have a severe allergic reaction, do not give another injection of COSENTYX.

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

Visit **COSENTYX.com** for more information.

REAL RESULTS. REAL RELIEF.*

NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (nr-axSpA)

Many people (38%) taking COSENTYX 150 mg (SC) felt at least a **40% improvement in overall symptoms at 1 year** vs 19% taking placebo. Many (41%) saw similar results in as little as 16 weeks vs 28% taking placebo.

40% OVERALL SYMPTOM IMPROVEMENT

*Results shown in clinical trials using subcutaneous (SC) administration (injection under the skin). The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.

COSENTYX can help with nr-axSpA symptoms so you don't have to fight as hard throughout your day.

In a clinical trial, people taking COSENTYX completed a survey by their doctors that measured how well their treatment was working.† The results showed overall improvements in symptoms of nr-axSpA:

- Total spinal pain
- Morning stiffness
- Fatigue
- Tenderness where tendons or ligaments connect to bones (enthesitis)
- Joint pain and swelling

†Bath Ankylosing Spondylitis Disease Activity Index.

IMPORTANT SAFETY INFORMATION (cont)
Severe skin reactions that look like eczema can happen during treatment with COSENTYX from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with COSENTYX if you develop severe skin reactions. Tell your doctor if you have any of the following signs or symptoms: redness or rash; itching; small bumps or patches; your skin is dry or feels like leather; blisters on the hands or feet that ooze or become crusty and skin peeling.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory infections.

These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

Visit **COSENTYX.com** for more information.

Cosentyx® (secukinumab)

HOW COSENTYX® WORKS

COSENTYX is different because it is the first and only IV infusion that targets IL-17A, one of the multiple molecules in the body that can cause inflammation in people with PsA, AS, and nr-axSpA.*

*The relationship between how COSENTYX works in the body and how it affects your symptoms are not fully known.

ABOUT COSENTYX

COSENTYX has been studied extensively for 16 years across all indications. COSENTYX was approved by the FDA in 2015 to treat moderate to severe plaque psoriasis. Then, in 2016, it was approved by the FDA to treat active ankylosing spondylitis and active psoriatic arthritis. In 2020, it was approved by the FDA to treat another form of axSpA: non-radiographic axial spondyloarthritis.

COSENTYX is the first and only IL-17A IV infusion for adults with PsA, AS, and nr-axSpA.

IMPORTANT SAFETY INFORMATION (cont)
Before using COSENTYX, tell your doctor if you:

- have any of the conditions or symptoms listed on page 4 for infections.
- have inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- are allergic to latex. The needle cap on the COSENTYX Sensoready® pen, and 150 mg/mL and 75 mg/0.5 mL prefilled syringes contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who take COSENTYX **should not** receive live vaccines. Children should be brought up to date with all vaccines before starting COSENTYX.
- have any other medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
- are pregnant or plan to become pregnant. It is not known if COSENTYX can harm your unborn baby. You and your doctor should decide if you will use COSENTYX.
- are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes into your breast milk.

WATCH THIS VIDEO TO LEARN MORE ABOUT HOW COSENTYX WORKS.

IMPORTANT SAFETY INFORMATION (cont)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

PREPARING FOR YOUR COSENTYX® INFUSION

Your healthcare provider will individualize your monthly, 30-minute infusion to your specific weight. COSENTYX does not require any additional medications (such as antihistamines) to be administered before or after your infusion.

- You will be given COSENTYX by a healthcare provider through a needle placed in a vein (infusion). It takes about 30 minutes to give you the full dose of COSENTYX.
- Your healthcare provider will tell you how often you should receive COSENTYX.
- If you miss an appointment to receive COSENTYX, make another appointment as soon as possible.

Talk to your healthcare provider about what to expect, as each infusion center may be different.

Here are a few considerations when preparing for your infusion.

BEFORE ARRIVING FOR YOUR INFUSION, YOU MAY BE ADVISED TO:

- Be well hydrated
- Dress comfortably
- Bring something to entertain yourself

DURING YOUR INFUSION, YOUR HEALTHCARE PROVIDER MAY:

- Check your vital signs
- Ask you some questions
- Answer any questions you may have

ONCE YOUR INFUSION IS COMPLETE:

- Schedule your next infusion
- If you miss an appointment to receive COSENTYX, make another appointment as soon as possible

Patient portrayal.

Things you can do during your 30-minute infusion:

- Listen to a favorite playlist or podcast
- Read a book
- Scroll through social media
- Play a game
- Catch up on emails

IMPORTANT SAFETY INFORMATION

Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

Cosentyx® (secukinumab)

NEED HELP?

SUPPORT:

If you need support starting or staying on COSENTYX, Novartis Patient Support is here to help.

COVERAGE:

Most insurers cover medications that are administered by your healthcare provider, such as COSENTYX infusions, **under your medical insurance rather than through your prescription insurance.**

CO-PAY SAVINGS:

Co-pay support may be available to help with the cost of your infusion appointment and COSENTYX prescription. That means if you have commercial or private prescription insurance, both COSENTYX and the administration may be covered.*

Call 1-844-267-3689 for more information.

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

IMPORTANT SAFETY INFORMATION (cont)

Infections

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have died from these infections.

- Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. **Do not take COSENTYX if you have an active TB infection**.

IMPORTANT SAFETY INFORMATION (cont)

Before starting COSENTYX, tell your doctor if you:

- are being treated for an infection
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal

Please see additional Important Safety Information throughout brochure. Tap here for full Prescribing Information, including Medication Guide.

Cosentyx®
(secukinumab)

Know the facts about taking COSENTYX® through IV Infusions:

- The first and only IV infusion of its kind*
- Approved for adults with PsA, AS, or nr-axSpA
- Administered once a month (every 4 weeks)
- A 30-minute infusion
- Individualized by your healthcare provider to your weight
- Does not require additional medications prior to your infusion
- The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory infections

*The first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.

If you need savings or support for COSENTYX, call Novartis Patient Support at 1-844-COSENTYX (1-844-267-3689).

Visit **COSENTYX.com**

Like us on Facebook at **@COSENTYX (secukinumab)**

See real stories from people taking COSENTYX on Instagram at **@COSENTYX (secukinumab)**

Please see Important Safety Information throughout brochure.
Tap here for full Prescribing Information, including Medication Guide.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

 10/23 299174